NYSE (USA) TSX (CANADA)

Directory of Stock Market Company

This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.

Search into NYSE and TSX
by quote, company name or key word

facebooktwitterlinkedin
Mail

RDEA - Ardea Biosciences Inc

Ardea Biosciences, Inc. ( Ardea), incorporated in January 1994, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad, previously called RDEA594, the Company’s lead clinical candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter. The Company’s next generation URAT1 inhibito","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"

# RDEAhart

Ardea Biosciences Inc News


Charming Shoppes Inc (NASDAQ:CHRS) shares were trading at $7.33 while... - Updated
The Mumbai Times - 5 hours ago
The 3 analysts offering 12-month price forecasts for Charming Shoppes Inc have a median target of 7.35, with a high estimate of 8.00 and a low estimate of 7.35.

Hot Biotech Stocks Traded by Hedge Funds in First Quarter
TheStreet.com - May 16, 2012
By Adam Feuerstein 05/16/12 - 07:10 AM EDT BOSTON (TheStreet) -- Noteworthy hedge fund trading in biotech and drug stocks, culled from the 13F filings for the first quarter: [Hedge funds and mutual funds that manage more than $100 million are required ...

10 Stocks With Recent Negative EPS Surprises And Broker Downgrades
Seeking Alpha - May 15, 2012
I ran a screen for potentially overvalued stocks which recently have failed to meet analyst estimates and have been downgraded by the brokers in the last week.

Ardea Biosciences Rating Lowered to Neutral at UBS AG (RDEA)
Daily Political - May 14, 2012
Ardea Biosciences (NASDAQ: RDEA) was downgraded by research analysts at UBS AG (NYSE: UBS) from a “buy” rating to a “neutral” rating in a report released on Friday.

Healthcare Sectors Showed Positive Momentum- OREX, ARNA, VVUS, DVAX, TEVA ...
eStocksDaily - May 14, 2012
Orexigen Therapeutics, Inc. (NASDAQ:OREX) diet-drug developer, jumped 20 percent to $4.03 on Friday in the wake of news that an advisory panel of the US Food and Drug Administration has suggested authorization of Arena Pharmaceuticals, ...

Equities Research Analysts' Downgrades for May, 11st (ALR, AMCX, BBY, GEOY ...
Junction Report - May 11, 2012
Alere Inc (NYSE: ALR) was downgraded by analysts at Leerink Swann to a “market perform” rating. AMC Networks (NASDAQ: AMCX) was downgraded by analysts at Gabelli to a “hold” rating.

Loss Widens at Ardea, Awaits Takeover - Analyst Blog
NASDAQ - May 9, 2012
Ardea Biosciences Inc. 's ( RDEA ) first quarter 2012 net loss of $1.25 per share was wider than the Zacks Consensus Loss Estimate of 97 cents and the year-ago loss of 59 cents per share.
Ardea Biosciences Rating Lowered to Hold at Canaccord Genuity (RDEA) - Daily Political

Tang Capital's Holdings: Insights Into Successful Investing
Seeking Alpha - May 7, 2012
Examining the regulatory filings of successful hedge funds can often give investors valuable insight into the thinking of top investment managers.

Ardea Biosciences Announces First Quarter 2012 Financial Results
MarketWatch (press release) - May 7, 2012
SAN DIEGO, CA, May 07, 2012 (MARKETWIRE via COMTEX) -- Ardea Biosciences, Inc. (NASDAQ:RDEA) , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today announced first quarter 2012 ...
Ardea Biosciences, Inc. (NASDAQ:RDEA) Investor Lawsuit filed to Block Merger ... - Your-Story.org (press release)
Ardea Biosciences Q1 Net Loss Widens - Quick Facts - RTT News

Securities Lawyers at Goldfarb LLP Seeking More Money, Information for ...
MarketWatch (press release) - May 1, 2012
DALLAS, May 1, 2012 /PRNewswire via COMTEX/ -- Securities lawyers at Goldfarb LLP announce an investigation into alleged violations of shareholder protection laws by officers and directors of Ardea Biosciences, Inc. (NASDAQ:RDEA) in connection with a ...

NYSE Media Coverage Selection of the best articles found in your favorit medias

Next Company >>